Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (764)	3/5/1998 5:01:00 PM
From: gy	Read Replies (1) \| Respond to of 1826

Following data will present in 9th Annual Meeting, American Association for Cancer Research March 28-April 1, 1998 New Orleans, LA #1553 MGI114, currently in phase I human trial, and scheduled for phase II human trial against a variety of solid tumors, was found to markedly inhibit tumor growth(p<0.001) in HL60/MRI myeloid leukemia xenograft model, at 7mg/kg(dailyx5,i.p.)and 10mg/kg(3x/week i.p.)for 3 weeks, with tumor growth inhibition significantly greater than that of other illudin analogs and several conventional antitumor agents. The result suggested MGI114 against myeloid leukemia should be evaluated in phase II clinic trials. #3585 Evidence of synergistic antitumor with MGI114 in combination with irinotecan(ITN) or 5-Fluorouracil(5-FU) against a human colon tumor xenograft model.